Inflammatory bowel diseases (including Crohn's disease, Ulcerative colitis, and others) and Irritable bowel syndrome are a group of disorders that affect the human gastrointestinal system. Interactions between microbiome and the intestinal cells are important in these chronic conditions. Enbiome Therapeutics lead “GutbiotiX” produces compounds that keep our intestinal epithelial cells happy and healthy. We have identified the key ingredient from human gut commensal microbe that could keep our intestinal cells healthy. We are evaluating the therapeutic potential of this gut commensal microbe in chronic inflammatory conditions affecting the gut. Our goal is to deliver the active ingredient of this microbe in a therapeutic yogurt format for affected patients.